Antimetabolite Immunosuppressant Drug Class List
✉ Email this page to a colleague
Drugs in Drug Class: Antimetabolite Immunosuppressant
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Azurity | MYHIBBIN | mycophenolate mofetil | SUSPENSION;ORAL | 216482-001 | May 1, 2024 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Azurity | MYHIBBIN | mycophenolate mofetil | SUSPENSION;ORAL | 216482-001 | May 1, 2024 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Azurity | MYHIBBIN | mycophenolate mofetil | SUSPENSION;ORAL | 216482-001 | May 1, 2024 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Novartis | MYFORTIC | mycophenolic sodium | TABLET, DELAYED RELEASE;ORAL | 050791-001 | Feb 27, 2004 | AB | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
| Novartis | MYFORTIC | mycophenolic sodium | TABLET, DELAYED RELEASE;ORAL | 050791-002 | Feb 27, 2004 | AB | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
